Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Animal Parasiticides Market Size & Share 2026-2035
Report ID: GMI2114
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Animal Parasiticides Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Animal Parasiticides Market Size
The global animal parasiticides market was valued at USD 13.69 billion in 2025, is anticipated to reach USD 14.71 billion in 2026, and is projected to advance at a 6.7% CAGR from 2026 to 2035, attaining USD 26.30 billion by 2035.
Animal Parasiticides Market Key Takeaways
Market Leader: Zoetis led with over 17.3% market share in 2025.
Leading Players: Top 5 players in this market include Zoetis, Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, which collectively held a market share of 55.3% in 2025.
The animal parasiticides market is evolving from episodic treatment toward preventive, protocol-led care across companion and food-producing animals. Demand is being shaped by expanding access to veterinary care, greater use of combination therapies, and a product mix that increasingly rewards broad-spectrum coverage, sustained protection, and easier administration.
GMI Analyst View
Based on our discussions with industry leaders, the animal parasiticides market sustained a 4.5% CAGR between 2022 and 2025, establishing the demand foundation from which the current forecast-period trajectory is projected to accelerate to 6.7% compounded annually through 2035—a meaningful step-up that reflects genuine broadening of both the treated animal base and the premium product mix rather than base-year distortion.
Animal Parasiticides Market Trends, Growth Drivers & GMI Forecast Outlook
Preventive companion-animal care, livestock-production intensity, and broader-spectrum formulations are expanding the market's revenue pool. The outlook depends on whether veterinary channels can convert greater treatment need into consistent adoption while preserving affordability in price-sensitive owner and producer populations.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Preventive care is becoming a more durable purchasing behavior as owners increasingly rely on veterinary recommendations for routine parasite control. The U.S. pet population included 87.3 million dogs and 76.3 million cats in 2025 [3]American Veterinary Medical Association. "U.S. Pet Ownership Statistics." avma.org, illustrating the scale of the addressable base for products that combine flea, tick, heartworm, and intestinal-parasite protection. For manufacturers, the commercial advantage lies not simply in more treated animals, but in the ability to retain them within recurring, premium prescription protocols.
Livestock demand follows a different operating logic. Poultry meat output reached 154.4 million tonnes in 2025 [2]Food and Agriculture Organization of the United Nations. "Food Outlook - November 2025." openknowledge.fao.org, and high-density production systems increase the economic consequences of unmanaged parasite loads through feed-conversion losses, morbidity, and treatment disruption. This favors products that fit established farm workflows, including feed, pour-on, injectable, and water-administered formats, while making efficacy, residue management, and veterinary guidance central to repeat use.
Innovation is also changing the value captured per treatment cycle. Combination products reduce the need for separate therapies, while long-acting injectable options can improve adherence where monthly owner-administered dosing is inconsistent. The resulting premiumization opportunity is strongest where veterinary practices have the capacity to explain clinical differentiation and maintain follow-up with animal owners.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Affordability can delay the shift from legacy or lower-priced products to multi-active prescription therapies, particularly when owners face consultation fees alongside recurring treatment costs. This creates a commercially important divide between markets where preventive care is embedded in annual veterinary routines and those where treatment remains more reactive or contingent on visible infestation.
In emerging economies, the same challenge is compounded by uneven clinic density, lower insurance penetration, and variable access to licensed supply. Animal populations may expand faster than the formal treatment infrastructure needed to convert that potential into dependable sales, limiting the pace at which premium products reach mass-market adoption.
Resistance management introduces an additional constraint for farm-animal suppliers. Prescription-linked use can improve treatment selection and longer-term parasite-control outcomes, but it also raises administrative and access hurdles for smaller producers. The market therefore faces a trade-off between improved stewardship and near-term friction in channels that previously relied on self-administered treatment.
GMI Analyst View
We see the central demand tension as the coexistence of premium preventive care in established companion-animal channels and cost-led purchasing in many farm and emerging-market settings. Suppliers that can pair clinically differentiated products with accessible distribution, disciplined pricing, and veterinary education will be better positioned to convert biological need into sustained treatment adherence.
Animal Parasiticides Market Segment Analysis
By Product Type
The animal parasiticides market's ectoparasiticides segment generated USD 7.94 billion in 2025 and is projected to grow at a 6.2% CAGR (2026-2035). Its scale reflects the entrenched role of flea, tick, lice, and mite control in companion-animal preventive care, alongside continued use of topical and pour-on products in livestock systems. Oral isoxazolines and convenient topical formats remain commercially influential because they align broad efficacy with owner-friendly dosing routines.
Endectocides generated USD 1.77 billion in 2025 and are forecast to advance at an 8.1% CAGR (2026-2035). The category benefits from demand for single-administration therapies that address internal and external parasites simultaneously. This proposition is especially compelling in veterinary settings and livestock operations seeking to simplify protocols while maintaining treatment consistency across diverse parasite burdens.
By Animal Type
The animal parasiticides market for companion animals generated USD 8.48 billion in 2025 and is expected to record a 7.5% CAGR (2026-2035). Pet humanization, recurring preventive-care routines, and demand for broad-spectrum oral and topical products are shifting the category toward higher-value prescription therapies. Dogs generated USD 5.51 billion in 2025 and accounted for 65% of companion-animal demand, while cats generated USD 1.86 billion and represented 22%; these species require differentiated formulations, but both support recurring demand through preventive treatment schedules.
Farm animals accounted for 38% of the market in 2025 and are projected to grow at a 5.4% CAGR (2026-2035). Purchasing patterns are shaped by herd size, local parasite pressure, production intensity, and the practicality of administering treatments across commercial operations. Cattle generated USD 1.66 billion in 2025 and represented 32% of farm-animal demand, reinforcing their importance to endectocide, anthelmintic, and ectoparasiticide suppliers serving grazing and feedlot systems.
By Type
Prescription parasiticides generated USD 9.31 billion in 2025 and are expected to grow at a 6.5% CAGR (2026-2035). Veterinary oversight supports the clinical positioning of combination therapies, particularly where product selection must account for animal health history, parasite exposure, and safety considerations. The channel is also advantaged by the emergence of veterinary-administered long-acting products that cannot be readily replicated through self-service purchasing.
OTC parasiticides held 32% of the market in 2025 and are forecast to expand at a 7.1% CAGR (2026-2035). Their accessibility is strategically important for cost-sensitive pet owners and livestock operators with limited veterinary access. E-commerce and consumer retail distribution strengthen the category's reach, although competitive pressure is likely to remain intense as branded products, generics, and value-oriented alternatives contend for price-conscious demand.
By Drug Class
Chemical synthetic parasiticides, led by isoxazoline products, generated USD 5.20 billion in 2025 and are projected to grow at an 8.2% CAGR (2026-2035). Their momentum reflects broad ectoparasite efficacy, convenient delivery formats, and expanding use in multi-active preventive regimens. Continued indication development can deepen their role in companion-animal care, provided suppliers sustain veterinary confidence in product differentiation and safety management.
Macrocyclic lactones represented 22% of the market in 2025 and are expected to expand at a 5.8% CAGR (2026-2035). The class remains foundational in parasite-control programs across cattle, sheep, horses, and companion animals, where it supports heartworm prevention and internal-parasite management. Its mature profile creates exposure to generic competition, but its broad installed base and established clinical familiarity preserve strategic relevance.
Pyrethroids generated USD 2.05 billion in 2025 and are forecast to grow at a 6.8% CAGR (2026–2035). Their cost profile sustains use in collars, topical applications, and farm-animal treatments, particularly where affordability remains decisive. However, competitive displacement is likely to persist in companion-animal settings as clinicians and owners place greater value on oral administration, combination coverage, and newer active ingredients.
Benzimidazoles held 10% of the market in 2025 and are projected to record a 6.0% CAGR (2026-2035). Their role in gastrointestinal parasite management supports continued adoption across livestock and companion-animal applications. The class retains particular value where dependable, cost-effective treatment is required, although resistance management and prescribing practices increasingly shape selection decisions.
Organophosphates generated USD 1.23 billion in 2025 and are expected to grow at a 3.2% CAGR (2026-2035). Their remaining commercial base is concentrated in lower-cost ectoparasite applications, including certain cattle and sheep use cases. Product substitution, safety scrutiny, and regulatory pressure are likely to constrain their long-term position relative to newer alternatives.
By End Use
Veterinary hospitals & clinics generated USD 7.11 billion in 2025 and are forecast to expand at a 6.0% CAGR (2026-2035). These settings are central to prescription initiation, diagnostics, adherence counseling, and administration of premium therapies. Their influence extends beyond direct dispensing because veterinarian recommendations shape product selection and reinforce preventive-care intervals.
Animal farms accounted for 34% of the market in 2025 and are expected to grow at a 5.8% CAGR (2026-2035). Demand in this setting depends on livestock-production economics, treatment practicality, resistance-control protocols, and veterinary access. Suppliers that provide products compatible with farm workflows and evidence-based treatment programs are better placed to secure repeat purchasing.
Home care settings generated USD 1.91 billion in 2025 and are projected to advance at a 10.5% CAGR (2026-2035). Digital commerce, retail availability, and demand for convenient self-administered products are expanding this channel's role. Its growth also intensifies the need for clear product guidance, as successful treatment depends on proper selection, dosing, and continuity.
GMI Analyst View
We believe the segment structure increasingly favors products that reduce treatment complexity without compromising clinical confidence. Broad-spectrum platforms can command stronger value capture, but the opportunity is not uniform: veterinary-led premium categories and consumer-led access channels will continue to evolve under different pricing, compliance, and competitive conditions.
Animal Parasiticides Market Regional Analysis
North America Animal Parasiticides Market Analysis
The animal parasiticides market in North America generated USD 5.75 billion in 2025 and is expected to account for 38% of global revenue by 2035. Its commercial depth stems from mature veterinary infrastructure, strong companion-animal preventive-care habits, and broad availability of prescription combination products. Continued growth will depend primarily on premium mix, product-cycle innovation, and the ability to preserve adherence in a cost-conscious consumer environment.
United States
The United States generated USD 4.31 billion in 2025 and is projected to grow at a 5.8% CAGR (2026-2035). The market is anchored by established veterinary use of oral isoxazoline and combination products, with long-acting injectable offerings adding a new clinical option. Scale, frequent veterinary interaction, and a deep base of branded-product awareness make the country a critical launch and commercialization market.
Europe Animal Parasiticides Market Analysis
Europe accounted for 25% of the market in 2025 and is projected to generate USD 6.05 billion by 2035. Companion-animal product demand is supported by established veterinary care, while livestock applications are increasingly influenced by prescription requirements and resistance-management practices. The region's regulatory direction favors more clinically supervised parasite control, a shift reflected in guidance on antiparasitic veterinary medicinal products [4]Health Products Regulatory Authority. "Antiparasitic Veterinary Medicinal Products." hpra.ie.
Asia Pacific Animal Parasiticides Market Analysis
The animal parasiticides market in Asia Pacific generated USD 3.01 billion in 2025 and is anticipated to reach USD 7.36 billion by 2035. Urban companion-animal adoption, livestock intensification, and improving veterinary-distribution infrastructure are widening the formal treatment base. The region's growth opportunity is substantial, but its realization depends on affordability, registration timelines, and the availability of trusted clinical and retail channels.
China
China generated USD 1.09 billion in 2025 and is projected to record a 10.5% CAGR (2026-2035). Companion-animal adoption in major cities is expanding demand for preventive veterinary care, while commercial poultry and swine operations sustain farm-animal use. The market's trajectory is strengthened by the coexistence of a large livestock base and a growing urban consumer segment willing to adopt higher-value products.
India
India generated USD 548.0 million in 2025 and is expected to expand at a 9.8% CAGR (2026-2035). Demand is led by cattle, buffalo, and small-ruminant applications, with companion-animal care becoming a secondary growth avenue in urban centers. The ability to broaden formal treatment access beyond major cities will be critical to converting animal population scale into durable market growth.
Japan
Japan generated USD 548.0 million in 2025 and is forecast to grow at a 6.8% CAGR (2026–2035). Its mature companion-animal market supports consistent use of preventive products, but demographic conditions limit the pace of new household formation. Product innovation and adherence within an established treatment base are consequently more important than rapid expansion in the number of animal owners.
South Korea
South Korea generated USD 274.0 million in 2025 and is expected to advance at a 6.5% CAGR (2026-2035). Rising pet ownership and veterinary engagement in urban areas are supporting demand for preventive treatments. The market offers a favorable environment for premium companion-animal products when product education, distribution, and consumer affordability are aligned.
Latin America Animal Parasiticides Market Analysis
Latin America represented 7% of the market in 2025 and is projected to generate USD 1.84 billion by 2035. The region combines an expanding urban companion-animal opportunity with significant livestock demand, particularly in cattle-oriented production systems. Distribution strength, local regulatory familiarity, and price discipline remain especially important because purchasing conditions vary widely between commercial farms and urban households.
Middle East & Africa Animal Parasiticides Market Analysis
The animal parasiticides market in the Middle East & Africa generated USD 547.7 million in 2025 and is projected to account for 4% of global revenue by 2035. A substantial livestock population creates a broad underlying need for parasite control, but realized demand remains constrained by uneven veterinary coverage, registration complexity, and smallholder price sensitivity. Improvements in service access and formal distribution are therefore essential to long-term market development.
GMI Analyst View
We view regional performance as a question of conversion rather than biological need alone. Mature markets must sustain value through innovation and adherence, whereas developing markets must expand the clinical, regulatory, and distribution systems that allow a large untreated or inconsistently treated animal base to enter reliable preventive-care channels.
Animal Parasiticides Market Share & Competitive Landscape
The animal parasiticides market share is moderately concentrated, with the top six companies accounting for 60.8% of global revenue in 2025. Competitive advantage rests on differentiated active ingredients, regulatory capabilities, trusted veterinary relationships, and the ability to commercialize products across prescription, retail, and livestock channels. Leading suppliers are increasingly competing on breadth of indication, duration of protection, and the convenience of administration rather than on single-parasite efficacy alone.
Zoetis held a 17.3% market share in 2025. Its competitive position is reinforced by the Simparica franchise and by its ability to sustain veterinary engagement around combination parasite-control protocols. Continued label development and platform extension are strategically important because they support differentiation in a category where recurring treatment recommendations influence brand persistence.
Merck Animal Health accounted for 13.9% of the market in 2025. The Bravecto franchise gives the company a substantial position in ectoparasiticide care, while its investment in oral, topical, and extended-release delivery options strengthens relevance across varied owner preferences and clinical settings. This portfolio breadth is particularly valuable as long-acting protection becomes a more prominent area of product competition.
Boehringer Ingelheim Animal Health held a 13.1% market share in 2025. The NexGard portfolio provides a foundation in companion-animal ectoparasiticide care, supported by broad geographic reach and established veterinary-practitioner relationships. Its ability to compete depends on maintaining franchise visibility as multi-active offerings broaden clinical expectations around parasite protection.
Elanco Animal Health combines prescription and consumer-accessible parasiticide brands across companion and farm-animal markets. Credelio, Seresto, and Advantage illustrate the strategic importance of maintaining exposure to both premium veterinary channels and value-conscious owner segments. Virbac and Ceva Sante Animale retain relevance through targeted veterinary and farm-animal portfolios, particularly in markets where local channel depth and specialist relationships can outweigh global scale.
Below the market leaders, Dechra Pharmaceuticals, Vetoquinol, Norbrook Laboratories, Phibro Animal Health, PetIQ, Neogen Corporation, Bimeda, Biogenesis Bago, and Ourofino Saude Animal compete through regional reach, generic and branded offerings, consumer access, livestock specialization, and local regulatory familiarity. Their role is most pronounced where price sensitivity, distributor relationships, and farm-specific treatment requirements create openings outside the broad global franchises.
Recent Industry Developments
On December 18, 2025, Elanco Animal Health received FDA conditional approval for Credelio Quattro-CA1 for the treatment of New World screwworm myiasis in dogs. The development extends the clinical relevance of a multi-active companion-animal product into an emergency-response use case and underscores the strategic value of adaptable isoxazoline-based platforms [5]Elanco Animal Health. "Elanco's Credelio Quattro-CA1 Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs." investor.elanco.com.
On August 13, 2026, Zoetis announced that the U.S. FDA granted Emergency Use Authorization for Simparica Trio for the treatment of New World screwworm infestations in dogs and puppies. The authorization demonstrates how established combination products can be deployed against emerging veterinary threats when their pharmacological profile supports an expanded use case [6]Zoetis. "Zoetis Receives Emergency Use Authorization for Simparica Trio for Treatment of New World Screwworm Infestations in Dogs and Puppies." investor.zoetis.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →